Nothing more than what was initially spoken of by the CEO. What I missed in the interview was the start of clinical trials. I heard first quarter but did not pay attention to 2009. Not sure how I missed that, but unless someone else knows different I do not see any interest until the trials are at least underway if not completed.
Market Data 
Markets 
AI
